Form 4: BioMarin Executive George Eric Davis Reports Stock Transactions

Executive Vice President and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, reports acquisition and disposal of company stock and stock options.

Summary

• On March 14, 2025, George Eric Davis, EVP, Chief Legal Officer of BioMarin Pharmaceutical Inc., disposed of 16,249 shares of common stock at a price of $69.44.
• Following this transaction, Davis directly owned 69,975 shares of common stock.
• On March 17, 2025, Davis acquired 12,940 shares of common stock at $0, representing restricted stock units.
• Following this acquisition, Davis directly owned 82,915 shares of common stock.
• On March 17, 2025, Davis acquired 30,020 stock options with an exercise price of $71.55, exercisable starting March 17, 2026, and expiring on March 16, 2035.
• Following this acquisition, Davis directly owned 30,020 stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider activity.

Positives

• The grant of 30,020 stock options to Davis could be seen as a positive incentive for his continued service and performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options suggests a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and exercise prices of these options are typically benchmarked against industry standards to ensure competitiveness and retention.

Stakeholder Impact

• Shareholders may be interested in the executive's stock transactions as an indicator of management's confidence in the company.
• Employees may view the stock option grants as a positive sign of the company's commitment to its leadership.

Key Dates